Robert Taub
Founder & Chairman @ MAN & SCIENCE
Brussels, Belgium
Robert Taub is a Series A investor at MAN & SCIENCE in Brussels focused on Biotechnology and Health Care. Robert Taub is the Co-Founder and Chairman at Nyxoah. He attended INSEAD.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Robert Taub invests in
Stages Robert Taub invests in
Countries Robert Taub invests in
Investment Focus
Industry
- Biotechnology 3 (75%)
- Health Care 2 (50%)
- Pharmaceutical 2 (50%)
- Medical 1 (25%)
- Hospital 1 (25%)
Stage
- Series A 1 (25%)
- Series B 1 (25%)
- Funding Round 1 (25%)
- Venture - Series Unknown 1 (25%)
Country
- Israel 2 (50%)
- Belgium 1 (25%)
- United Kingdom 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
EyeD Pharma
|
EyeD Pharma is a pharmaceutical company dedicated to the development of innovative drug products in ophthalmology. EyeD Pharma focuses on the treatment of glaucoma. Traditionally, glaucoma is treated by administering eye drops every day for the rest of the patient’s life. | $51M / Venture - Series Unknown / Dec 24, 2021 | |
ARCHIMEDICX
|
RateCare is the easiest way to understand hospital quality. We rate, rank and benchmark hospitals with a scientific, unbiased method for important decisions. Our system is powered by a unique and HIMSS certified-unbiased algorithm developed by ARCHIMEDICX, which runs on one of the largest hospital procedural databases. Our data and tools areavailable for patients, hospitals and companies needing to make healthcare price/quality decisions. The RateCare team is dedicated to a patient-centric, transparent and sensible approach to measuring Hospital quality and pricing worldwide. Join us on www.ratecare.com | $3M / Jan 01, 2015 | |
LifeBond
|
LifeBond is a leader in the development and manufacturing of bio-surgical medical devices for tissue repair that are intended to improve the recovery of patients and to create an environment that supports the body’s natural healing process and promotes tissue repair. Of natural origin, elastic, adhesive, durable and yet absorbable, the company’sdevices can be used to fill a long list of unmet surgical needs. LifeBond’s first product, LifeSeal™, is designed to provide staple-line reinforcement in bariatric and colorectal operations. It was recently studied in an international pilot clinical study in Europe. The company’s second pipeline product, LifeMesh™, a self-fixating hernia mesh, is in pre-clinical development. Other pipeline products include tissue adhesives and absorbable hemostats. LifeSeal™, LifeMesh™ and other LifeBond™ products are investigational and have not yet been approved for sale in the US or in any other market. For more information please visit use at: www.life-bond.com | $8M / Series B / Jun 03, 2009 | |
NeuroDerm
|
NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhancedclinical efficacy. | $2.5M / Series A / Jul 23, 2007 |
Co-Investors
About MAN & SCIENCE
MAN & SCIENCE Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Robert Taub
Founder & Chairman
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Robert Taub invest in?
Robert Taub invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Robert Taub last invest?
The most recent investment recorded for Robert Taub closed in Dec 2021. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
